DURHAM, N.C., Nov. 14, 2024 (GLOBE NEWSWIRE) -- . (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, ...

Minimally invasive techniques require only small incisions, reducing the likelihood of complications and promoting a quicker ...

In recent years, significant strides in research and development have led to the creation of new and more effective biomaterials, particularly those with enhanced biocompatibility, mechanical strength ...

Organogenesis (NASDAQ:ORGO – Get Free Report) will release its earnings data after the market closes on Tuesday, November ...

Humacyte ( (HUMA) ) has released its Q3 earnings. Here is a breakdown of the information Humacyte presented to its investors. Humacyte, Inc., a ...

DURHAM, N.C., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at ...

The researchers' recently published study describes a way to re-activate apoptosis in mutated cells, which would amount to ...

The global surgical sphincteroplasty market is on a trajectory of significant growth, projected to expand from USD 1.8 billion in 2024 to an estimated USD 3 billion by 2034. This growth reflects a ...

Investigational product demonstrated superior hemodialysis vascular access outcomes compared with autologous arteriovenous ...

As a reminder, Humacyte, Inc. is a Durham, North Carolina based late clinical-stage life sciences concern focus on the development of bioengineered regenerative human tissues that can be implanted ...